Ready-made stem cell therapies for pets could be coming
San Diego startup Gallant secured $18 million to develop the first FDA-approved stem cell therapy for veterinary use, potentially revolutionizing pet treatment.
MAIN POINTS
- Gallant received $18 million in funding for stem cell therapy development.
- The therapy aims to be the first FDA-approved for veterinary medicine.
- Successful approval could transform treatment options for pets.
- Stem cell therapy remains an experimental field despite ongoing research.
TAKEAWAYS
- Gallant's funding highlights investor confidence in veterinary stem cell therapy.
- FDA approval is crucial for the therapy's market introduction.
- The development could significantly impact veterinary medicine practices.
- Continued research is essential for advancing stem cell therapy applications.